SGHERZA, NICOLA
 Distribuzione geografica
Continente #
NA - Nord America 880
AS - Asia 711
EU - Europa 549
SA - Sud America 190
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.369
Nazione #
US - Stati Uniti d'America 853
SG - Singapore 301
IT - Italia 225
BR - Brasile 144
CN - Cina 124
HK - Hong Kong 105
RU - Federazione Russa 85
VN - Vietnam 65
SE - Svezia 49
DE - Germania 48
FR - Francia 41
GB - Regno Unito 28
IN - India 18
AR - Argentina 17
BD - Bangladesh 16
CI - Costa d'Avorio 14
ID - Indonesia 13
FI - Finlandia 12
CA - Canada 11
TR - Turchia 11
AT - Austria 9
BE - Belgio 9
MX - Messico 9
NL - Olanda 9
JP - Giappone 8
CO - Colombia 7
IQ - Iraq 7
PK - Pakistan 7
PL - Polonia 7
UZ - Uzbekistan 7
IE - Irlanda 6
CL - Cile 5
EC - Ecuador 5
KR - Corea 5
MA - Marocco 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
PE - Perù 4
TN - Tunisia 4
UA - Ucraina 4
VE - Venezuela 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
EG - Egitto 3
ES - Italia 3
JM - Giamaica 3
PH - Filippine 3
PY - Paraguay 3
TW - Taiwan 3
EU - Europa 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CU - Cuba 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
IL - Israele 1
KZ - Kazakistan 1
LS - Lesotho 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 2.369
Città #
Singapore 174
Ashburn 148
San Jose 106
Hong Kong 85
Beijing 57
Fairfield 46
Chandler 43
Nyköping 42
Los Angeles 29
Seattle 29
Woodbridge 29
New York 28
Bari 26
Ho Chi Minh City 24
Houston 24
Milan 22
Wilmington 18
Lauterbourg 17
Santa Clara 17
Falkenstein 15
Abidjan 14
Ann Arbor 14
Cambridge 14
Frankfurt am Main 13
Hanoi 11
Jakarta 11
Lawrence 11
Helsinki 10
Inglewood 10
London 10
São Paulo 10
Brussels 9
Des Moines 9
Roxbury 8
Buffalo 7
Council Bluffs 7
Gesualdo 7
Moscow 7
Munich 7
Nuremberg 7
Tashkent 7
Dallas 6
Naples 6
Salt Lake City 6
Vienna 6
Atlanta 5
Brooklyn 5
Chennai 5
Chicago 5
Florianópolis 5
Johannesburg 5
San Diego 5
San Francisco 5
Warsaw 5
Alcamo 4
Bitonto 4
Denver 4
Dublin 4
Imbersago 4
Istanbul 4
Modugno 4
Orem 4
Paris 4
Princeton 4
Rome 4
Seoul 4
Tokyo 4
Avellino 3
Baku 3
Belo Horizonte 3
Bengaluru 3
Boardman 3
Bắc Ninh 3
Casablanca 3
Chiswick 3
Da Nang 3
Florence 3
Guangzhou 3
Hải Dương 3
Magé 3
Montreal 3
Palermo 3
Phoenix 3
Phú Thọ 3
Taranto 3
Verona 3
Andria 2
Aparecida de Goiânia 2
Bauru 2
Belford Roxo 2
Betim 2
Birmingham 2
Bisceglie 2
Bogotá 2
Boston 2
Brasília 2
Brno 2
Bà Rịa 2
Campinas 2
Cariacica 2
Totale 1.388
Nome #
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 187
Challenges and opportunities of MicroRNAs in lymphomas 137
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 131
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 116
What Is New in the Treatment of Smoldering Multiple Myeloma? 103
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 103
null 96
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 93
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 92
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 87
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 86
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 82
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 70
null 68
Effects of daratumumab on hematopoietic stem cell collection and engraftment in multiple myeloma patients eligible for autologous transplantation: results of the real-life PRIMULA study comparing bortezomib, thalidomide and dexamethasone (VTd) with VTd plus daratumumab (D-VTd) as induction therapy 67
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 67
Dasatinib first-line: Multicentric Italian experience outside clinical trials 67
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 62
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 62
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials 60
Implications of interleukin-6 (Il-6)-blockade for severe covid-19 infection in patients with multiple myeloma 58
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 56
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 55
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 52
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese” 48
Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review 46
Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” 45
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia 44
Latent tuberculosis infection detected by quantiferon-TB assay in patients with multiple myeloma receiving novel drugs: focus on reactivation prophylaxis in a retrospective, single-center study 44
Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments 43
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease 42
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry 38
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 35
Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese 23
Totale 2.465
Categoria #
all - tutte 10.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.564


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 0 0 0 0 0 4 7 1
2021/2022120 21 8 0 8 6 9 14 5 5 7 21 16
2022/2023139 14 29 14 7 5 16 4 24 20 0 6 0
2023/2024186 26 31 26 8 15 28 28 5 0 0 6 13
2024/2025591 22 7 30 24 16 71 69 57 21 17 104 153
2025/20261.216 183 58 90 132 175 66 107 36 206 163 0 0
Totale 2.465